SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021

Importance Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. Objective To determine the cumulative incidence of infection with SARS-CoV-2, from a randomly selected sample of individuals normally resident at three Health and Demographic Surveillance Systems (HDSSs) in Kenya. Design This was a cross-sectional population-based serosurvey conducted at Kilifi HDSS, Nairobi Urban HDSS, and Manyatta HDSS in Kenya. We selected age-stratified samples at HDSSs in Kilifi, Kisumu and Nairobi, in Kenya. Blood samples were collected from participants between 01 Dec 2020 and 27 May 2021. Setting Kilifi HDSS comprises a predominantly rural population, Manyatta HDSS comprises a predominantly semi-urban population, while Nairobi Urban HDSS comprises an urban population. The total population under regular surveillance at the three sites is ~470,000. Exposure We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Locally validated assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. Main Outcome and Measures The primary outcome measure was cumulative incidence of infection with SARS-COV-2 virus as evidenced by seropositivity to SARS-CoV-2 whole spike protein. We adjusted our estimates using classical methods and Bayesian modelling to account for assay performance. We performed multivariable logistic regression to test associations between seropositivity and age category, time period and sex. Results We recruited 2,559 individuals from the three HDSS sites, median age (IQR) 27years (10-78) and 52% were female. Seroprevalence at all three sites rose steadily during the study period. In Kilifi, Kisumu and Nairobi, seroprevalences at the beginning of the study were 14.5 % (9.1-21), 36.0 (28.2-44.4) and 32.4 % (23.1-42.4) respectively; at the end they were 27.6 % (21.4-33.9), 42.0 % (34.7-50.0) and 50.2 % (39.7-61.1), respectively. In multivariable logistic regression models that adjusted for sex and period of sample collections, age category was strongly associated with seroprevalence (p<0.001), with the highest seroprevalences being observed in the 35-44 and [≥]65 year age categories. Conclusion There has been substantial unobserved transmission of SARS-CoV-2 in the general population in Kenya. There is wide variation in cumulative incidence by location and age category.

[1]  M. McMorrow,et al.  Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virus–Infected and Uninfected Persons: A Cross-Sectional Household Survey , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Scott,et al.  Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations , 2021, Journal of Clinical Virology.

[3]  J. Scott,et al.  Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels , 2021, Nature Communications.

[4]  M. Hoelscher,et al.  Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe , 2021, EClinicalMedicine.

[5]  J. Hasenauer,et al.  Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities , 2021, The Lancet Global Health.

[6]  S. Tollman,et al.  SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021 , 2021, Emerging infectious diseases.

[7]  M. Masika,et al.  High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya , 2021, International Journal of Infectious Diseases.

[8]  J. Scott,et al.  Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021. , 2021, JAMA.

[9]  P. Munywoki,et al.  Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020 , 2021, F1000Research.

[10]  J. Scott,et al.  Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya , 2021, Nature Communications.

[11]  M. Keeling,et al.  COVID-19 transmission dynamics underlying epidemic waves in Kenya , 2021, Science.

[12]  J. Scott,et al.  Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya , 2021, Open forum infectious diseases.

[13]  J. Lessler,et al.  Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 , 2021, Emerging infectious diseases.

[14]  J. Scott,et al.  Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya , 2021, medRxiv.

[15]  J. Scott,et al.  Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals , 2021, medRxiv.

[16]  J. Nkengasong,et al.  The puzzle of the COVID-19 pandemic in Africa , 2020, Science.

[17]  E. Hod,et al.  Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum , 2020, Nature Immunology.

[18]  J. Scott,et al.  Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.

[19]  A. Gelman,et al.  Bayesian Analysis of Tests with Unknown Specificity and Sensitivity , 2020, medRxiv.

[20]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[21]  S. Madhi,et al.  Health and Demographic Surveillance Systems Within the Child Health and Mortality Prevention Surveillance Network , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Blessing Mberu,et al.  Health & Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic Surveillance System (NUHDSS). , 2015, International journal of epidemiology.

[23]  M. McMorrow,et al.  Seroprevalence of SARS-CoV-2 after the Second Wave in South Africa in HIV-Infected and Uninfected Persons: A Cross-Sectional Household Survey, November 2020 – April 2021 , 2021, SSRN Electronic Journal.

[24]  Kevin Marsh,et al.  HEALTH AND DEMOGRAPHIC SURVEILLANCE SYSTEM PROFILE Profile: The Kilifi Health and Demographic Surveillance System (KHDSS) , 2012 .

[25]  B. Gladen,et al.  Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.